Masimo Corp. Hits New 52-Week High of $179.99, Up 41.51%

Masimo Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 179.99 on June 9, 2026. This achievement underscores the company's strong performance, with a remarkable one-year return of 41.51%, significantly outpacing the S&P 500's 22.99% gain during the same period. The company's market capitalization stands at USD 13,145 million, reflecting its solid position within the industry. Masimo Corp. boasts a price-to-earnings (P/E) ratio of 63.00, indicating investor confidence in its growth prospects. Additionally, the company has demonstrated impressive management efficiency, highlighted by a return on equity (ROE) of 29.07% and a return on capital employed (ROCE) of 28.40%. Masimo's financial health is further supported by a low debt-to-equity ratio of 0.53 and a debt-to-EBITDA ratio of 1.51 times, showcasing its strong ability to service debt. With consistent positive results over the last three quarters and a healthy annual net sales growth rate of 5.95%, Masimo Corp. continues to solidify its position in the market.